No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report
S E M Vonk1, S W J Terheggen-Lagro2, L M Mouissie3
1Department of Hospital Pharmacy, Amsterdam University Medical Centers, location AMC, the Netherlands.
Abstract:
In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis. Exposure to tezacaftor, ivacaftor and its metabolites was assessed by determination of the area under the plasma concentration versus time curve (AUC0-24 h for tezacaftor and AUC0-12 h for ivacaftor and its metabolite) before start of clofazimine and 8 and 115 days after start of clofazimine. The AUC-ratio at day 115 and pre-start was 1.09, 1.45 and 0.747 for ivacaftor, hydroxymethyl ivacaftor and tezacaftor, respectively. This case suggests that clofazimine exhibits no clinically relevant increase in exposure to tezacaftor and ivacaftor.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Therapeutic Drug Monitoring: Affecting Factors
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combined Effects of Drugs: Synergism
Such synergistic combinations...


